Honey bee venom allergen-IgE-TCR-FcεRI immunological complex

The honey bee venom allergen-IgE-TCR-FcεRI immunological complex is the central molecular assembly driving Type I hypersensitivity reactions in honey bee venom (HBV) allergy. This interactome involves the binding of major HBV allergens, such as Phospholipase A2 (Api m 1), to allergen-specific IgE antibodies (https://pubmed.ncbi.nlm.nih.gov/28643910/). These IgE antibodies are typically bound to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils; allergen-mediated cross-linking of these receptors triggers the release of inflammatory mediators like histamine, leading to symptoms ranging from local reactions to systemic anaphylaxis (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100510/). Furthermore, the complex includes the presentation of allergen peptides by Major Histocompatibility Complex (MHC) Class II molecules to T-cell receptors (TCRs), which promotes a Th2-polarized immune response and the production of more IgE (https://pubmed.ncbi.nlm.nih.gov/29330404/). Therapeutic management often involves Venom Immunotherapy (VIT), which uses standardized venom extracts to induce immune tolerance by increasing blocking IgG4 antibodies and regulatory T-cell activity (https://www.jacionline.org/article/S0091-6749(17)31134-6/fulltext). Additionally, the anti-IgE monoclonal antibody Omalizumab can be used to sequester free IgE, thereby reducing FcεRI expression and preventing effector cell activation (https://pubmed.ncbi.nlm.nih.gov/24581432/).

Other names

Patient IgE antibodies and T-cell receptors recognizing honey bee venom allergens presented on MHC complexes and FcεRI-bound IgE on effector cellsHoney bee venom allergy pathwayHBV hypersensitivity complexApi m 1-IgE-FcεRI axisHymenoptera venom allergy interactome

The primary mechanisms include the sequestration of free IgE by monoclonal antibodies to prevent receptor binding, and the induction of immune tolerance through venom immunotherapy, which shifts the T-cell response from Th2 to Th1/Treg and increases the production of allergen-specific IgG4 blocking antibodies.